A compound selected from compounds of the following formula, and pharmaceutically acceptable salts, hydrates, and solvates thereof: wherein: - J 1 and -J 3 taken together form -CH 2 CH 2 -; and wherein: - Q is independently pyrid-2-yl; and has n substituents -R F; or - Q is independently pyrimidin-2-yl; and has n substituents -R F; wherein: n is independently 0, 1, 2, or 3; and wherein: each -R F is independently -R Z, -F, -Cl, -CF 3, -OH, -OR Z, -OCF 3, -CN, -NH 2, -NHR ZZ, -NR ZZ 2, azetidino, pyrrolidino, piperidino, piperazino, morpholino, or azepino; wherein each -R Z is independently saturated aliphatic C 1-6 alkyl or saturated C 3-6 cycloalkyl, and is optionally substituted with one or more substituents selected from -F, -OH, -OR ZZ, -OCH 2 F, -OCHF 2, and -OCF 3; wherein each -R ZZ is independently saturated aliphatic C 1-4 alkyl; and wherein each azetidino, pyrrolidino, piperidino, piperazino, morpholino, and azepino is optionally substituted with one or more saturated aliphatic C 1-4 alkyl groups; and wherein: - Y is independently -OH, -OR YA, -F, -Cl, or -CN; wherein -R YA is independently saturated aliphatic C 1-6 alkyl; and wherein: - R A1 is independently -H or -R AA; - R A2 is independently -H or -R AA; each -R AA is independently -R AA1, -F, -Cl, or -CN; and wherein: each -R AA1 is independently saturated aliphatic C 1-4 alkyl, and is optionally substituted with one or more groups -F; and wherein: - R B1 is independently -H or -R BB; - R B2 is independently -H or -R BB; wherein: each -R BB is independently -R BB1, -F, -Cl, or -CN; and each -R BB1 is independently saturated aliphatic C 1-4 alkyl, and is optionally substituted with one or more groups -F; and wherein: - R N is independently -H or -R NN; - R NN is independently saturated aliphatic C 1-4 alkyl. - J 1 and -J 3 taken together form -CH 2 CH 2 -; - Q is independently pyrid-2-yl; and has n substituents -R F; or - Q is independently pyrimidin-2-yl; and has n substituents -R F; n is independently 0, 1, 2, or 3; each -R F is independently -R Z, -F, -Cl, -CF 3, -OH, -OR Z, -OCF 3, -CN, -NH 2, -NHR ZZ, -NR ZZ 2, azetidino, pyrrolidino, piperidino, piperazino, morpholino, or azepino; wherein each -R Z is independently saturated aliphatic C 1-6 alkyl or saturated C 3-6 cycloalkyl, and is optionally substituted with one or more substituents selected from -F, -OH, -OR ZZ, -OCH 2 F, -OCHF 2, and -OCF 3; wherein each -R ZZ is independently saturated aliphatic C 1-4 alkyl; and wherein each azetidino, pyrrolidino, piperidino, piperazino, morpholino, and azepino is optionally substituted with one or more saturated aliphatic C 1-4 alkyl groups; - Y is independently -OH, -OR YA, -F, -Cl, or -CN; wherein -R YA is independently saturated aliphatic C 1-6 alkyl; - R A1 is independently -H or -R AA; - R A2 is independently -H or -R AA; each -R AA is independently -R AA1, -F, -Cl, or -CN; and each -R AA1 is independently saturated aliphatic C 1-4 alkyl, and is optionally substituted with one or more groups -F; - R B1 is independently -H or -R BB; - R B2 is independently -H or -R BB; each -R BB is independently -R BB1, -F, -Cl, or -CN; and each -R BB1 is independently saturated aliphatic C 1-4 alkyl, and is optionally substituted with one or more groups -F; - R N is independently -H or -R NN; - R NN is independently saturated aliphatic C 1-4 alkyl.